{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:32:48Z","timestamp":1789435968256,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clcc.2025.10.005","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:27:16Z","timestamp":1761121636000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapy-Induced Metastatic Melanoma During Treatment With Encorafenib and Cetuximab for BRAF-Mutated Colorectal Cancer: A Case Report and Short Literature Review"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8605-4290","authenticated-orcid":false,"given":"Nerina","family":"Denaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato M.","family":"Marsicano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveva","family":"Mortellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Murgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Passoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2025.10.005_bib0001","unstructured":"Taira AA-O, Aavikko M, Katainen R, et al. Comprehensive metabolomic and epigenomic characterization of microsatellite stable BRAF-mutated colorectal cancer. LID - 10.1038\/s41388-025-03326-y [doi]. (1476-5594)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0002","unstructured":"Napolitano S, Ciardiello D, Cioli E, et al. BRAFV600E mutant metastatic colorectal cancer: current advances in personalized treatment and future perspectives. (1532-1967)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0003","unstructured":"AIOM. Linee guida TUMORI DEL COLON. 2024."},{"key":"10.1016\/j.clcc.2025.10.005_bib0004","unstructured":"Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus Cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study. (1527-7755)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0005","unstructured":"Tabernero J, Velez L, Trevino TL, et al."},{"key":"10.1016\/j.clcc.2025.10.005_bib0006","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2025.10.005_bib0007","unstructured":"Kopetz SA-O, Yoshino TA-O, Van Cutsem EA-O, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. (1546-170X)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0008","unstructured":"Elez E, Yoshino T, Shen L, et al."},{"key":"10.1016\/j.clcc.2025.10.005_bib0009","unstructured":"Chen D, Huang JF, Liu K, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. (1932-6203)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0010","unstructured":"Lao VV, Grady WM. Epigenetics and colorectal cancer. (1759-5053)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0011","unstructured":"Lochhead P, Kuchiba A Fau - Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. (1460-2105)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0012","unstructured":"Meneguzzo A, Lazzarotto A, Alaibac M. Eruptive melanocytic Nevi secondary to Encorafenib for BRAF mutant metastatic colorectal cancer. (1791-7549)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0013","unstructured":"Perry BM, Nguyen A, Desmond BL, Blattner CM, Thomas RS, Young RJ. Eruptive nevi associated with medications (ENAMs). (1097-6787 [Electronic])."},{"key":"10.1016\/j.clcc.2025.10.005_bib0014","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s12094-018-1891-7","article-title":"Cutaneous toxicities of new treatments for melanoma","volume":"20","author":"Boada","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ejhpharm-2020-002347","article-title":"The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis","volume":"28","author":"Peng","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.clcc.2025.10.005_bib0016","unstructured":"McClenahan P, Lin LL, Tan JM, et al. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. (2168-6084)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0017","unstructured":"Lenga M, Venkatesh S, Choi JN. Eruptive nevi in the setting of encorafenib: a case report and literature review. (2352-5126 [Print])."},{"key":"10.1016\/j.clcc.2025.10.005_bib0018","unstructured":"Alfallouji YA-O, Spencer AA-O, Calonje E, et al. Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases. (1365-2230)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0019","unstructured":"Anforth RM, Carlos GR, Scolyer RA, Chou S, Fernandez-Pe\u00f1as P. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. (1473-5636 [Electronic])."},{"key":"10.1016\/j.clcc.2025.10.005_bib0020","unstructured":"Mikami H, Akasaka E, Nakano H, Sawamura D Eruptive melanocytic nevi associated with encorafenib and cetuximab combination therapy. (1346-8138 [Electronic])."},{"key":"10.1016\/j.clcc.2025.10.005_bib0021","unstructured":"Alevizopoulos N, Alexandris D, Pavlakis MG, Dimosthenous K, Pavlakis G. Concurrent eruptive melanocytic nevi and multiple keratoacanthomas induced by Encorafenib. (2168-8184)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0022","unstructured":"Omori R, Miyagaki TA-O, Miyano K, Hashimoto Y, Kadono TA-O Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient. (1346-8138)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0023","unstructured":"Lam K, Gates GA, Bach DQ, Cheng K Eruptive melanocytic Nevi in the setting of Encorafenib, Cetuximab, and Binimetinib combination Therapy: a case report. (1662-6567)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0024","unstructured":"Nazir ZH, Haliasos HC, Busam KJ, Marchetti MA, Linos K, Marghoob AA. Acquired melanocytic Nevi mimicking acral lentiginous melanoma in a patient taking a BRAF inhibitor. (2168-6084)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0025","unstructured":"Boccaccino A, Borelli B, Intini R, et al. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. (2059-7029)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0026","unstructured":"Schmitt L, Schumann T Fau - Inhoff O, et al. Eruptive Nevi mimicking wart-like lesions under selective BRAF inhibition in a 37-year-old female melanoma patient. (1662-6567)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0027","unstructured":"Ma L, Dominguez AR, Collins GR, Kia KF, Cockerell CJ. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. (1538-3652)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0028","unstructured":"Specchio F, Argenziano G, Tiodorovic-Zivkovic D, et al. Dermoscopic clues to diagnose acantholytic dyskeratosis. (2160-9381 [Print])."},{"key":"10.1016\/j.clcc.2025.10.005_bib0029","unstructured":"Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. (1538-3652)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0030","unstructured":"Gerami P, Sorrell J, Martini M. Dermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib. (1097-6787)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0031","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2025.10.005_bib0032","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2025.10.005_bib0033","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Dalle","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2025.10.005_bib0034","first-page":"27","article-title":"Appearance of new Vemurafenib-associated melanocytic Nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with Vemurafenib","volume":"6","author":"Cohen","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/jdv.12449","article-title":"Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients","volume":"29","author":"Vanneste","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0036","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0037","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0038","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1111\/ajd.12776","article-title":"Darier disease-like hyperkeratotic papules and invasive squamous cell carcinoma in a patient with melanoma treated with dabrafenib","volume":"59","author":"Babuna Kobaner","year":"2018","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0039","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0040","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0041","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaad.2015.01.018","article-title":"Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy","volume":"72","author":"Anforth","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0042","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2025.10.005_bib0043","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","article-title":"Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma","volume":"71","author":"Sanlorenzo","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0044","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamadermatol.2014.4115","article-title":"Multiple BRAF wild-type melanomas during Dabrafenib treatment for metastatic BRAF-mutant melanoma","volume":"151","author":"Carrera","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0045","unstructured":"Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. (1527-7755 [Electronic])."},{"key":"10.1016\/j.clcc.2025.10.005_bib0046","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.annder.2008.04.016","article-title":"Eruptive nevi associated with sorafenib treatment","volume":"135","author":"Bennani-Lahlou","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0047","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0048","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0049","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4103\/ijd.ijd_87_21","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"66","author":"Chen","year":"2021","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0050","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-4632.2010.04822.x","article-title":"Sorafenib-induced premalignant and malignant skin lesions","volume":"50","author":"Williams","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0051","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/j.1524-4725.2009.01289.x","article-title":"Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors","volume":"35","author":"Smith","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clcc.2025.10.005_bib0052","first-page":"308","article-title":"Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib","volume":"10","author":"Lynch","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0053","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2008.10.043","article-title":"The histologic spectrum of epithelial neoplasms induced by sorafenib","volume":"61","author":"Kwon","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0054","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s13256-021-03037-4","article-title":"Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report","volume":"15","author":"Abbas","year":"2021","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clcc.2025.10.005_bib0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clcc.2025.10.005_bib0056","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.144.6.779","article-title":"Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib","volume":"144","author":"Hong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0057","first-page":"169","article-title":"Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma","volume":"9","author":"Diamantis","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clcc.2025.10.005_bib0058","unstructured":"Tak E, An HI, Lee AS, et al. Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer. (1432-0851)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0059","unstructured":"Seidman JS, Eichenfield DZ, Orme CM. Nevoid melanoma and eruptive nevi from erlotinib. LID - 13030\/qt47q8p2w7 [pii]. (1087-2108)."},{"key":"10.1016\/j.clcc.2025.10.005_bib0060","unstructured":"Hemperly S, Ermolovich T, Lountzis NI, Sheikh HA, Purcell SM. Darkening and eruptive nevi during treatment with erlotinib. (2326-6929)."}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002825000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002825000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:01:09Z","timestamp":1778817669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002825000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1533002825000866"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2025.10.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-Induced Metastatic Melanoma During Treatment With Encorafenib and Cetuximab for BRAF-Mutated Colorectal Cancer: A Case Report and Short Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}